Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
4.1300-0.0400 (-0.96%)
At close: 04:00PM EST
4.1300 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.1700
Open4.2300
Bid4.0500 x 1400
Ask4.2000 x 1200
Day's Range4.0550 - 4.2400
52 Week Range4.0000 - 7.4450
Volume869,173
Avg. Volume856,638
Market Cap616.902M
Beta (5Y Monthly)1.25
PE Ratio (TTM)44.89
EPS (TTM)0.0920
Earnings DateFeb 24, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
57% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AMRX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amneal Pharmaceuticals, Inc.
    Daily – Vickers Top Insider Picks for 12/02/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Business Wire

    Amneal Receives Approval for Difluprednate Ophthalmic Emulsion

    BRIDGEWATER, N.J., November 19, 2021--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for difluprednate ophthalmic emulsion 0.05%, which is the generic version of Durezol® and is used in the treatment of inflammation and pain associated with ocular surgery.

  • Business Wire

    Amneal to Virtually Participate at Upcoming Investor Conferences

    BRIDGEWATER, N.J., November 12, 2021--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") today announced that its investor relations or management team will virtually attend the following investor conferences:

  • Insider Monkey

    15 Best Single-Digit Stocks to Buy Now

    In this article, we discuss the 15 best single-digit stocks to buy now. You can skip our detailed analysis of the single-digit stocks, and go directly to see the 5 Best Single-Digit Stocks to Buy Now. In this article, we will mention some of the best cheap stocks under $10. It’s suitable for beginner investors […]

Advertisement
Advertisement